Lasorsa, F.; di Meo, N.A.; Rutigliano, M.; Milella, M.; Ferro, M.; Pandolfo, S.D.; Crocetto, F.; Tataru, O.S.; Autorino, R.; Battaglia, M.;
et al. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. Biomedicines 2023, 11, 1071.
https://doi.org/10.3390/biomedicines11041071
AMA Style
Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, Tataru OS, Autorino R, Battaglia M,
et al. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. Biomedicines. 2023; 11(4):1071.
https://doi.org/10.3390/biomedicines11041071
Chicago/Turabian Style
Lasorsa, Francesco, Nicola Antonio di Meo, Monica Rutigliano, Martina Milella, Matteo Ferro, Savio Domenico Pandolfo, Felice Crocetto, Octavian Sabin Tataru, Riccardo Autorino, Michele Battaglia,
and et al. 2023. "Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice" Biomedicines 11, no. 4: 1071.
https://doi.org/10.3390/biomedicines11041071
APA Style
Lasorsa, F., di Meo, N. A., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S. D., Crocetto, F., Tataru, O. S., Autorino, R., Battaglia, M., Ditonno, P., & Lucarelli, G.
(2023). Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. Biomedicines, 11(4), 1071.
https://doi.org/10.3390/biomedicines11041071
